Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference Conference (Transcript)
04:30pm, Monday, 06'th Mar 2023
Biogen Inc. (NASDAQ:BIIB ) 43rd Annual Cowen Healthcare Conference Call March 6, 2023 9:50 AM ET Company Participants Christopher Viehbacher - Chief Executive Officer Conference Call Participants Phil
Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi
09:47am, Monday, 06'th Mar 2023
The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.
FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July
09:27am, Monday, 06'th Mar 2023
Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.
3 Biotech Stocks To Watch Ahead Of March 2023
03:44pm, Saturday, 25'th Feb 2023
Do you have these three biotech stocks on your watchlist right now?
How Are Biotech ETFs Reacting to Q4 Earnings Releases?
03:48pm, Tuesday, 21'st Feb 2023
The latest earnings from some of the big biotech players came in at mixed this reporting season.
Biogen shares fall on 4Q results but Canaccord analysts remain optimistic about Alzheimer's drug
02:56pm, Wednesday, 15'th Feb 2023
Biogen Inc (NASDAQ:BIIB) shares fell Wednesday after the company reported declining fourth-quarter sales and revealed that it expects that trend to continue in 2023. The company expects sales to dec
Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key Metrics
01:33pm, Wednesday, 15'th Feb 2023
Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall
Biogen Boss Turns Corner on Alzheimer's Miscues
01:16pm, Wednesday, 15'th Feb 2023
The biotech company needs to embark on new growth path as former Sanofi CEO Chris Viehbacher takes the helm.
Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up
12:03pm, Wednesday, 15'th Feb 2023
Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.
Biogen Inc. (BIIB) Q4 2022 Earnings Call Transcript
12:00pm, Wednesday, 15'th Feb 2023
Biogen Inc. (NASDAQ:BIIB ) Q4 2022 Results Conference Call February 15, 2023 8:00 AM ET Company Participants Mike Hencke - Head, Investor Relations Christopher Viehbacher - CEO Michael McDonnell - Chi
Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates
09:47am, Wednesday, 15'th Feb 2023
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen's stock gains after company beats Q4 revenue and earnings expectations
07:24am, Wednesday, 15'th Feb 2023
Shares of Biogen Inc. BIIB, -0.48% gained about 1.7% in premarket trading on Wednesday after the company beat revenue and earnings expectations in the fourth quarter. Biogen had earnings of $550.4 mil
2 Top Biotech Stocks Defying the Bear Market
02:00pm, Wednesday, 08'th Feb 2023
These stocks soared in the double digits last year.
Sage and Biogen's NDA for Depression Drug Gets Priority Review
03:17pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.
BIIB Stock: 1.64% Increase Explanation
02:24am, Tuesday, 07'th Feb 2023
The stock price of Biogen Inc (NASDAQ: BIIB) increased by 1.64% in the most recent trading session. This is why.
